Emdin, Connor A. http://orcid.org/0000-0002-2385-8259
Khera, Amit V.
Chaffin, Mark http://orcid.org/0000-0002-1234-5562
Klarin, Derek
Natarajan, Pradeep
Aragam, Krishna
Haas, Mary
Bick, Alexander
Zekavat, Seyedeh M.
Nomura, Akihiro
Ardissino, Diego
Wilson, James G.
Schunkert, Heribert
McPherson, Ruth
Watkins, Hugh
Elosua, Roberto
Bown, Matthew J.
Samani, Nilesh J.
Baber, Usman
Erdmann, Jeanette http://orcid.org/0000-0002-4486-6231
Gupta, Namrata
Danesh, John
Chasman, Daniel
Ridker, Paul
Denny, Joshua
Bastarache, Lisa
Lichtman, Judith H.
D’Onofrio, Gail
Mattera, Jennifer
Spertus, John A.
Sheu, Wayne H.-H.
Taylor, Kent D.
Psaty, Bruce M.
Rich, Stephen S.
Post, Wendy
Rotter, Jerome I.
Chen, Yii-Der Ida
Krumholz, Harlan
Saleheen, Danish http://orcid.org/0000-0001-6193-020X
Gabriel, Stacey
Kathiresan, Sekar http://orcid.org/0000-0002-6724-032X
Article History
Received: 3 October 2017
Accepted: 21 March 2018
First Online: 24 April 2018
Competing interests
: A.V.K. is supported by a John S. LaDue Memorial Fellowship at Harvard Medical School, and a KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst funded by the National Institutes of Health (NIH) (TR001100) and has received consulting fees from Merck and Amarin. P.N. reports funding from the John S. LaDue Memorial Fellowship at Harvard Medical School and has received consulting fees from Amarin. S.K. is supported by a research scholar award from Massachusetts General Hospital, the Donovan Family Foundation, and R01 HL127564; he has received a research grant from Bayer Healthcare; and consulting fees from Merck, Novartis, Sanofi, AstraZeneca, Alnylam Pharmaceuticals, Leerink Partners, Noble Insights, MedGenome, Aegerion Pharmaceuticals, Regeneron Pharmaceuticals, Quest Diagnostics, Genomics PLC, and Eli Lilly and Company; and holds equity in San Therapeutics and Catabasis Pharmaceuticals. The remaining authors declare no competing interests.